Meditation as a therapeutic intervention for adults at risk for Alzheimer's disease - Potential benefits and underlying mechanisms

Frontiers in Psychiatry

Volumn 5, Issue APR, 2014, Pages

  Innes, Kim E ^a,b   Selfe, Terry Kit ^a,b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cellular aging; Cognitive impairment; Epigenetics; Meditation; Mind body therapies; Mood; Sleep; Stress

Indexed keywords

ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; CELL SURVIVAL; COGNITIVE DEFECT; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; GLUCOSE UTILIZATION; HIGH RISK PATIENT; HIPPOCAMPUS; HUMAN; IMMUNE RESPONSE; LIFESTYLE; MEDITATION; MORBIDITY; MORTALITY; PSYCHOLOGICAL WELL BEING; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; VAGUS TONE;

EID: 84901009933     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2014.00040     Document Type: Short Survey

References (171)

1. Gauthier S. Should we encourage the use of high-dose vitamin E in persons with memory complaints as a preventive strategy against Alzheimer's disease? J Psychiatry Neurosci (2000) 25(4):394.
2. National Center for Health Statistics (2004). Available from: http://www.cdc.gov/nchs/fastats/deaths.htm.
3. Alzheimer's Association. 2014 Alzheimer's Disease Facts and Figures. Alzheimers Dement (2014) 10(2):1-75.
4. Khalsa DS. Mindfulness effects on caregiver stress: should we expect more? J Altern Complement Med (2010) 16(10):1025-6. doi:10.1089/acm.2010.0431.
5. Logsdon RG, Teri L. The Pleasant Events Schedule-AD: psychometric properties and relationship to depression and cognition in Alzheimer's disease patients. Gerontologist (1997) 37(1):40-5. doi:10.1093/geront/37.1.40.
6. Teri L. Behavior and caregiver burden: behavioral problems in patients with Alzheimer disease and its association with caregiver distress. Alzheimer Dis Assoc Disord (1997) 11(4):S35-8.
7. Lu YF, Haase JE. Experience and perspectives of caregivers of spouse with mild cognitive impairment. Curr Alzheimer Res (2009) 6(4):384-91. doi:10.2174/156720509788929309.
8. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA (2002) 288(12):1475-83. doi:10.1001/jama.288.12.1475.
9. Rosenberg PB, Mielke MM, Appleby B, Oh E, Leoutsakos JM, Lyketsos CG. Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. Int J Geriatr Psychiatry (2011) 26(4):364-72. doi:10.1002/gps.2535.
10. Ryu S-H, Lee K-J. Neuropsychiatric symptoms in patients with mild cognitive impairment and mild Alzheimer's disease in the community-dwelling elderly in Korea. Alzheimers Dementia (2008) 4(Suppl 1):T450. doi:10.1016/j.jalz.2008.05.1343.
11. Rongve A, Boeve BF, Aarsland D. Frequency and correlates of caregiver-reported sleep disturbances in a sample of persons with early dementia. J Am Geriatr Soc (2010) 58(3):480-6. doi:10.1111/j.1532-5415.2010.02733.x.
12. Winter Y, Korchounov A, Zhukova TV, Bertschi NE. Depression in elderly patients with Alzheimer dementia or vascular dementia and its influence on their quality of life. J Neurosci Rural Pract (2011) 2(1):27-32. doi:10.4103/0976-3147.80087.
13. Panza F, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Imbimbo BP, et al. Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am J Geriatr Psychiatry (2010) 18(2):98-116. doi:10.1097/JGP.0b013e3181b0fa13.
14. Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectr (2008) 13(1):45-53.
15. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol (2003) 2(1):15-21. doi:10.1016/S1474-4422(03)00262-X.
16. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand (2009) 119(4):252-65. doi:10.1111/j.1600-0447.2008.01326.x.
17. Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dementia (2010) 6(1):11-24. doi:10.1016/j.jalz.2009.10.002.
18. Loewenstein D, Greig M, Schinka J, Barker W, Shen Q, Potter E, et al. An investigation of PreMCI: subtypes and longitudinal outcomes. Alzheimers Dement (2012) 8(3):172-9. doi:10.1016/j.jalz.2011.03.002.
19. Reisberg B, Gauthier S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease. Int Psychogeriatr (2008) 20(1):1-16. doi:10.1017/S1041610207006412.
20. Jessen F, Wolfsgruber S, Wiese B, Bickeld H, Mösch E, Kaduszkiewicz H, et al. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimer Dement (2014) 10(1):76-83. doi:10.1016/j.jalz.2012.09.017.
21. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet (2006) 367(9518):1262-70. doi:10.1016/S0140-6736(06)68542-5.
22. Reisberg B, Prichep L, Mosconi L, John ER, Glodzik-Sobanska L, Boksay I, et al. The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease. Alzheimers Dementia (2008) 4(Suppl 1):S98-108. doi:10.1016/j.jalz.2007.11.017.
23. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 8(7):619-27. doi:10.1016/S1474-4422(09)70139-5.
24. Woods DL, Phillips LR, Martin JL. Biological basis for sleep disturbance and behavioral symptoms in dementia: a biobehavioral model. Res Gerontol Nurs (2011) 4(4):281-93. doi:10.3928/19404921-20110302-01.
25. Beaulieu-Bonneau S, Hudon C. Sleep disturbances in older adults with mild cognitive impairment. Int Psychogeriatr (2009) 21(4):654-66. doi:10.1017/S1041610209009120.
26. Guarnieri B, Adorni F, Musicco M, Appollonio I, Bonanni E, Caffarra P, et al. Prevalence of sleep disturbances in mild cognitive impairment and dementing disorders: a Multicenter Italian Clinical Cross-Sectional Study on 431 patients. Dement Geriatr Cogn Disord (2012) 33(1):50-8. doi:10.1159/000335363.
27. Schofield PW, Marder M, Dooneief G, Jacobs DM, Sano M, Stern Y. Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. Am J Psychiatry (1997) 154(5):609-15.
28. Palmer K, Berger AK, Monastero R, Winblad B, Backman L, Fratiglioni L. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology (2008) 68(19):1596-602. doi:10.1212/01.wnl.0000260968.92345.3f.
29. Lee DR, Thomas AJ. Sleep in dementia and caregiving-assessment and treatment implications: a review. Int Psychogeriatr (2011) 23(2):190-201. doi:10.1017/S1041610210001894.
30. McCurry SM, Logsdon RG, Teri L, Vitiello MV. Sleep disturbances in caregivers of persons with dementia: contributing factors and treatment implications. Sleep Med Rev (2007) 11(2):143-53. doi:10.1016/j.smrv.2006.09.002.
31. Valimaki TH, Vehvilainen-Julkunen KM, Pietila AM, Pirttila TA. Caregiver depression is associated with a low sense of coherence and health-related quality of life. Aging Ment Health (2009) 13(6):799-807. doi:10.1080/13607860903046487.
32. Reagan LP, Grillo CA, Piroli GG. The As and Ds of stress: metabolic, morphological and behavioral consequences. Eur J Pharmacol (2008) 585(1):64-75. doi:10.1016/j.ejphar.2008.02.050.
33. Schulz R, Martire LM. Family caregiving of persons with dementia: prevalence, health effects, and support strategies. Am J Geriatr Psychiatry (2004) 12(3):240-9. doi:10.1176/appi.ajgp.12.3.240.
34. Alspaugh ME, Stephens MA, Townsend AL, Zarit SH, Greene R. Longitudinal patterns of risk for depression in dementia caregivers: objective and subjective primary stress as predictors. Psychol Aging (1999) 14(1):34-43. doi:10.1037/0882-7974.14.1.34.
35. Lovell B, Wetherell MA. The cost of caregiving: endocrine and immune implications in elderly and non elderly caregivers. Neurosci Biobehav Rev (2011) 35(6):1342-52. doi:10.1016/j.neubiorev.2011.02.007.
36. Dimsdale JE. Psychological stress and cardiovascular disease. J Am Coll Cardiol (2008) 51(13):1237-46. doi:10.1016/j.jacc.2007.12.024.
37. Vitaliano PP, Scanlan JM, Zhang J, Savage MV, Hirsch IB, Siegler IC. A path model of chronic stress, the metabolic syndrome, and coronary heart disease. Psychosom Med (2002) 64(3):418-35.
38. Wilson RS, Arnold SE, Schneider JA, Kelly JF, Tang Y, Bennett DA. Chronic psychological distress and risk of Alzheimer's disease in old age. Neuroepidemiology (2006) 27(3):143-53. doi:10.1159/000095761.
39. Wilson RS, Schneider JA, Boyle PA, Arnold SE, Tang Y, Bennett DA. Chronic distress and incidence of mild cognitive impairment. Neurology (2007) 68(24):2085-92. doi:10.1212/01.wnl.0000264930.97061.82.
40. Wilson RS, Arnold SE, Schneider JA, Li Y, Bennett DA. Chronic distress, age-related neuropathology, and late-life dementia. Psychosom Med (2007) 69(1):47-53. doi:10.1097/01.psy.0000250264.25017.21.
41. Innes KE, Vincent HK, Taylor AG. Chronic stress and insulin resistance-related indices of cardiovascular disease risk, part I: neurophysiological responses and pathological sequelae. Altern Ther Health Med (2007) 13(4):46-52.
42. Kim JJ, Diamond DM. The stressed hippocampus, synaptic plasticity and lost memories. Nat Rev Neurosci (2002) 3(6):453-62.
43. Lucassen PJ, Heine VM, Muller MB, van der Beek EM, Wiegant VM, De Kloet ER, et al. Stress, depression and hippocampal apoptosis. CNS Neurol Disord Drug Targets (2006) 5(5):531-46. doi:10.2174/187152706778559273.
44. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev (2005) 4(2):141-94. doi:10.1016/j.arr.2005.03.003.
45. Lucassen PJ, Meerlo P, Naylor AS, van Dam AM, Dayer AG, Fuchs E, et al. Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: implications for depression and antidepressant action. Eur Neuropsychopharmacol (2010) 20(1):1-17. doi:10.1016/j.euroneuro.2009.08.003.
46. Innes KE, Vincent HK, Taylor AG. Chronic stress and insulin resistance-related indices of cardiovascular disease risk, part 2: a potential role for mind-body therapies. Altern Ther Health Med (2007) 13(5):44-51.
47. Hellstrom HR. The altered homeostatic theory: a hypothesis proposed to be useful in understanding and preventing ischemic heart disease, hypertension, and diabetes-including reducing the risk of age and atherosclerosis. Med Hypotheses (2007) 68(2):415-33. doi:10.1016/j.mehy.2006.05.031.
48. Lee PY, Yun AJ, Bazar KA. Conditions of aging as manifestations of sympathetic bias unmasked by loss of parasympathetic function. Med Hypotheses (2004) 62(6):868-70. doi:10.1016/j.mehy.2003.11.024.
49. Raber J. Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation. From obesity to memory deficits. Mol Neurobiol (1998) 18(1):1-22. doi:10.1007/BF02741457.
50. Starr VL, Convit A. Diabetes, sugar-coated but harmful to the brain. Curr Opin Pharmacol (2007) 7(6):638-42. doi:10.1016/j.coph.2007.10.007.
51. Skoog I. Vascular aspects in Alzheimer's disease. J Neural Transm Suppl (2000) 59:37-43.
52. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry (2006) 11(8):721-36. doi:10.1038/sj.mp.4001854.
53. Gottfries CG, Balldin J, Blennow K, Brane G, Karlsson I, Regland B, et al. Regulation of the hypothalamic-pituitary-adrenal axis in dementia disorders. Ann N Y Acad Sci (1994) 746:336-43. doi:10.1111/j.1749-6632.1994.tb39253.x.
54. Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Innate Inflam Stroke (2010) 1207:155-62. doi:10.1111/j.1749-6632.2010.05726.x.
55. McEwen BS. Sex, stress and the hippocampus: allostasis, allostatic load and the aging process. Neurobiol Aging (2002) 23(5):921-39. doi:10.1016/S0197-4580(02)00027-1.
56. Steffens DC, Otey E, Alexopoulos GS, Butters MA, Cuthbert B, Ganguli M, et al. Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry (2006) 63(2):130-8. doi:10.1001/archpsyc.63.2.130.
57. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust (2009) 190(7 Suppl):S54-60.
58. Cohen BE, Panguluri P, Na B, Whooley MA. Psychological risk factors and the metabolic syndrome in patients with coronary heart disease: findings from the Heart and Soul Study. Psychiatry Res (2010) 175(1/2):133-7. doi:10.1016/j.psychres.2009.02.004.
59. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry (2010) 67(3):220-9. doi:10.1001/archgenpsychiatry.2010.2.
60. Chodosh J, Kado DM, Seeman TE, Karlamangla AS. Depressive symptoms as a predictor of cognitive decline: MacArthur studies of successful aging. Am J Geriatr Psychiatry (2007) 15(5):406-15. doi:10.1097/01.JGP.0b013e31802c0c63.
61. Beaudreau SA, O'Hara R. Late-life anxiety and cognitive impairment: a review. Am J Geriatr Psychiatry (2008) 16(10):790-803. doi:10.1097/JGP.0b013e31817945c3.
62. Copeland MP, Daly E, Hines V, Mastromauro C, Zaitchik D, Gunther J, et al. Psychiatric symptomatology and prodromal Alzheimer's disease. Alzheimer Dis Assoc Disord (2003) 17(1):1-8. doi:10.1097/00002093-200301000-00001.
63. Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem Res (2007) 32(10):1749-56. doi:10.1007/s11064-007-9385-y.
64. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev (2007) 87(3):873-904. doi:10.1152/physrev.00041.2006.
65. Boeve BF. Update on the diagnosis and management of sleep disturbances in dementia. Sleep Med Clin (2008) 3(3):347-60. doi:10.1016/j.jsmc.2008.04.010.
66. Dauvilliers Y. Insomnia in patients with neurodegenerative conditions. Sleep Med (2007) 8:S27-34. doi:10.1016/S1389-9457(08)70006-6.
67. Cole CS, Richards KC. Sleep and cognition in people with Alzheimer's disease. Issues Ment Health Nurs (2005) 26(7):687-98. doi:10.1080/01612840591008258.
68. Xu L, Jiang CQ, Lam TH, Liu B, Jin YL, Zhu T, et al. Short or long sleep duration is associated with memory impairment in older Chinese: the Guangzhou Biobank Cohort Study. Sleep (2011) 34(5):575-80.
69. Peterson MJ, Benca RM. Sleep in mood disorders. Sleep Med Clin (2008) 3:231-49. doi:10.1016/j.jsmc.2008.01.009.
70. McEwen BS. Sleep deprivation as a neurobiologic and physiologic stressor: allostasis and allostatic load. Metabolism (2006) 55(10 Suppl 2):S20-3. doi:10.1016/j.metabol.2006.07.008.
71. Innes KE, Selfe TK, Taylor AG. Menopause, the metabolic syndrome, and mind-body therapies. Menopause (2008) 15(5):1005-13. doi:10.1097/01.gme.0b013e318166904e.
72. Miller MA, Cappuccio FP. Inflammation, sleep, obesity and cardiovascular disease. Curr Vasc Pharmacol (2007) 5(2):93-102. doi:10.2174/157016107780368280.
73. Suarez EC. Self-reported symptoms of sleep disturbance and inflammation, coagulation, insulin resistance and psychosocial distress: evidence for gender disparity. Brain Behav Immunity (2008) 22(6):960-8. doi:10.1016/j.bbi.2008.01.011.
74. Trenell MI, Marshall NS, Rogers NL. Sleep and metabolic control: waking to a problem? Clin Exp Pharmacol Physiol (2007) 34(1-2):1-9. doi:10.1111/j.1440-1681.2007.04541.x.
75. Biessels GJ, Kappelle LJ. Utrecht Diabetic Encephalopathy Study G. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans (2005) 33(Pt 5):1041-4. doi:10.1042/BST20051041.
76. Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep (2007) 7(5):373-80. doi:10.1007/s11910-007-0058-7.
77. Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, Jagust W, et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc (2005) 53(7):1101-7. doi:10.1111/j.1532-5415.2005.53360.x.
78. Rosano C, Newman AB. Cardiovascular disease and risk of Alzheimer's disease. Neurol Res (2006) 28(6):612-20. doi:10.1179/016164106X130407.
79. Foley D, Ancoli-Israel S, Britz P, Walsh J. Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res (2004) 56(5):497-502. doi:10.1016/j.jpsychores.2004.02.010.
80. Apostolova LG, Thompson PM. Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment. Neuropsychologia (2006) 46(6):1597-612. doi:10.1016/j.neuropsychologia.2007.10.026.
81. Corey-Bloom J. Treatment trials in aging and mild cognitive impairment. Curr Top Behav Neurosci (2012) 10:347-56. doi:10.1007/7854_2011_153.
82. Bonadonna R. Meditation's impact on chronic illness. Holist Nurs Pract (2003) 17(6):309-19. doi:10.1097/00004650-200311000-00006.
83. Dorland WAN. Dorland's Illustrated Medical Dictionary. 32nd ed. Philadelphia: Saunders (2012). 2147 p.
84. Innes KE, Bourguignon C, Taylor AG. Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review. J Am Board Fam Pract (2005) 18(6):491-519. doi:10.3122/jabfm.18.6.491.
85. Schneider RH, Walton KG, Salerno JW, Nidich SI. Cardiovascular disease prevention and health promotion with the transcendental meditation program and Maharishi consciousness-based health care. Ethn Dis (2006) 16(3 Suppl 4):S4-15.
86. Innes KE, Selfe TK, Vishnu A. Mind-body therapies for menopausal symptoms: a systematic review. Maturitas (2010) 66(2):135-49. doi:10.1016/j.maturitas.2010.01.016.
87. Selfe TK, Innes KE. Mind-body therapies and osteoarthritis of the knee. Curr Rheumatol Rev (2009) 5(4):204-11. doi:10.2174/157339709790192512.
88. Waelde LC, Thompson L, Gallagher-Thompson D. A pilot study of a yoga and meditation intervention for dementia caregiver stress. J Clin Psychol (2004) 60(6):677-87. doi:10.1002/jclp.10259.
89. Lane JD, Seskevich JE, Pieper CF. Brief meditation training can improve perceived stress and negative mood. Altern Ther Health Med (2007) 13(1):38-44.
90. Innes KE, Selfe TK, Brown C, Rose K, Thompson-Heisterman A. The effects of meditation on perceived stress and related indices of psychological status and sympathetic activation in persons with Alzheimer's disease and their caregivers: a pilot study. Evid Based Complement Alternat Med (2012) 2012:927509. doi:10.1155/2012/927509.
91. Moss A, Wintering N, Roggenkamp H, Khalsa DS, Waldman MR, Monti D, et al. Effects of an eight week meditation program on mood and anxiety in patients with memory loss. J Altern Complement Med (2012) 18(1):48-53. doi:10.1089/acm.2011.0051.
92. Jayadevappa R, Johnson JC, Bloom BS, Nidich S, Desai S, Chhatre S, et al. Effectiveness of transcendental meditation on functional capacity and quality of life of African Americans with congestive heart failure: a randomized control study. Ethn Dis (2007) 17(1):72-7.
93. Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosom Med (2003) 65(4):571-81. doi:10.1097/01.PSY.0000074003.35911.41.
94. Sharma VK, Das S, Mondal S, Goswami U, Gandhi A. Effect of Sahaj Yoga on neuro-cognitive functions in patients suffering from major depression. Indian J Physiol Pharmacol (2006) 50(4):375-83.
95. Khalsa DS, Newberg A. Kirtan Kriya meditation: a promising technique for enhancing cognition in memory-impaired older adults. In: Hartman-Stein PE, Rue AL editors. Enhancing Cognitive Fitness in Adults: A Guide to the Use and Development of Community-Based Programs. New York: Springer (2011). p. 419-31.
96. Curiati JA, Bocchi E, Freire JO, Arantes AC, Braga M, Garcia Y, et al. Meditation reduces sympathetic activation and improves the quality of life in elderly patients with optimally treated heart failure: a prospective randomized study. J Altern Complement Med (2005) 11(3):465-72. doi:10.1089/acm.2005.11.465.
97. Paul-Labrador M, Polk D, Dwyer JH, Velasquez I, Nidich S, Rainforth M, et al. Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease. Arch Intern Med (2006) 166(11):1218-24. doi:10.1001/archinte.166.11.1218.
98. Rubia K. The neurobiology of meditation and its clinical effectiveness in psychiatric disorders. Biol Psychol (2009) 82(1):1-11. doi:10.1016/j.biopsycho.2009.04.003.
99. Epel E, Daubenmier J, Moskowitz JT, Folkman S, Blackburn E. Can meditation slow rate of cellular aging? Cognitive stress, mindfulness, and telomeres. Ann N Y Acad Sci (2009) 1172:34-53. doi:10.1111/j.1749-6632.2009.04414.x.
100. Manikonda JP, Stork S, Togel S, Lobmuller A, Grunberg I, Bedel S, et al. Contemplative meditation reduces ambulatory blood pressure and stress-induced hypertension: a randomized pilot trial. J Hum Hypertens (2008) 22(2):138-40. doi:10.1038/sj.jhh.1002275.
101. Newberg AB, Iversen J. The neural basis of the complex mental task of meditation: neurotransmitter and neurochemical considerations. Med Hypotheses (2003) 61(2):282-91. doi:10.1016/S0306-9877(03)00175-0.
102. Kjaer TW, Bertelsen C, Piccini P, Brooks D, Alving J, Lou HC. Increased dopamine tone during meditation-induced change of consciousness. Brain Res Cogn Brain Res (2002) 13(2):255-9. doi:10.1016/S0926-6410(01)00106-9.
103. Lazar SW, Kerr CE, Wasserman RH, Gray JR, Greve DN, Treadway MT, et al. Meditation experience is associated with increased cortical thickness. Neuroreport (2005) 16(17):1893-7. doi:10.1097/01.wnr.0000186598.66243.19.
104. Gutman SA, Schindler VP. The neurological basis of occupation. Occup Ther Int (2007) 14(2):71-85. doi:10.1002/oti.225.
105. Newberg AB, Wintering N, Khalsa DS, Roggenkamp H, Waldman MR. Meditation effects on cognitive function and cerebral blood flow in subjects with memory loss: a preliminary study. J Alzheimers Dis (2010) 20(2):517-26. doi:10.3233/JAD-2010-1391.
106. Newberg AB, Wintering N, Waldman MR, Amen D, Khalsa DS, Alavi A. Cerebral blood flow differences between long-term meditators and non-meditators. Conscious Cogn (2010) 19(4):899-905. doi:10.1016/j.concog.2010.05.003.
107. Srinivasan N, Baijal S. Concentrative meditation enhances preattentive processing: a mismatch negativity study. Neuroreport (2007) 18(16):1709-12. doi:10.1097/WNR.0b013e3282f0d2d8.
108. Pagnoni G, Cekic M. Age effects on gray matter volume and attentional performance in Zen meditation. Neurobiol Aging (2007) 28(10):1623-7. doi:10.1016/j.neurobiolaging.2007.06.008.
109. Tang YY, Ma Y, Wang J, Fan Y, Feng S, Lu Q, et al. Short-term meditation training improves attention and self-regulation. Proc Natl Acad Sci U S A (2007) 104(43):17152-6. doi:10.1073/pnas.0707678104.
110. Rainforth MV, Schneider RH, Nidich SI, Gaylord-King C, Salerno JW, Anderson JW. Stress reduction programs in patients with elevated blood pressure: a systematic review and meta-analysis. Curr Hypertens Rep (2007) 9(6):520-8. doi:10.1007/s11906-007-0094-3.
111. Rosenzweig S, Reibel DK, Greeson JM, Edman JS, Jasser SA, McMearty KD, et al. Mindfulness-based stress reduction is associated with improved glycemic control in type 2 diabetes mellitus: a pilot study. Altern Ther Health Med (2007) 13(5):36-8.
112. Sinha S, Singh SN, Monga YP, Ray US. Improvement of glutathione and total antioxidant status with yoga. J Altern Complement Med (2007) 13(10):1085-90. doi:10.1089/acm.2007.0567.
113. McBee L. Mindfulness-Based Elder Care. A CAM Model for Frail Elders and Their Caregivers. New York: Springer Publishing Company (2008).
114. Lantz MS, Buchalter EN, McBee L. The Wellness Group: a novel intervention for coping with disruptive behavior among [corrected] elderly nursing home residents [erratum appears in Gerontologist 1997 Oct; 37(5):687]. Gerontologist (1997) 37(4):551-6.
115. Lindberg DA. Integrative review of research related to meditation, spirituality, and the elderly. Geriatr Nurs (2005) 26(6):372-7. doi:10.1016/j.gerinurse.2005.09.013.
116. Pradhan EK, Baumgarten M, Langenberg P, Handwerger B, Gilpin AK, Magyari T, et al. Effect of mindfulness-based stress reduction in rheumatoid arthritis patients. Arthritis Rheum (2007) 57(7):1134-42. doi:10.1002/art.23010.
117. Sephton SE, Salmon P, Weissbecker I, Ulmer C, Floyd A, Hoover K, et al. Mindfulness meditation alleviates depressive symptoms in women with fibromyalgia: results of a randomized clinical trial. Arthritis Rheumatism (2007) 57(1):77-85. doi:10.1002/art.22478.
118. Walton KG, Schneider RH, Salerno JW, Nidich SI. Psychosocial stress and cardiovascular disease. Part 3: clinical and policy implications of research on the transcendental meditation program. Behav Med (2005) 30(4):173-83. doi:10.3200/BMED.30.4.173-184.
119. Allen NB, Chambers R, Knight W. Melbourne Academic Mindfulness Interest G. Mindfulness-based psychotherapies: a review of conceptual foundations, empirical evidence and practical considerations. Aust N Z J Psychiatry (2006) 40(4):285-94. doi:10.1111/j.1440-1614.2006.01794.x.
120. Wang DJJ, Rao HY, Korczykowski M, Wintering N, Pluta J, Khalsa DS, et al. Cerebral blood flow changes associated with different meditation practices and perceived depth of meditation. Psychiatry Res Neuroimaging (2011) 191(1):60-7. doi:10.1016/j.pscychresns.2010.09.011.
121. Lavretsky H, Epel ES, Siddarth P, Nazarian N, Cyr NS, Khalsa DS, et al. A pilot study of yogic meditation for family dementia caregivers with depressive symptoms: effects on mental health, cognition, and telomerase activity. Int J Geriatr Psychiatry (2013) 28(1):57-65. doi:10.1002/gps.3790.
122. Andrews NP, Fujii H, Goronzy JJ, Weyand CM. Telomeres and immunological diseases of aging. Gerontology (2010) 56(4):390-403. doi:10.1159/000268620.
123. Franco S, Blasco MA, Siedlak SL, Harris PL, Moreira PI, Perry G, et al. Telomeres and telomerase in Alzheimer's disease: epiphenomena or a new focus for therapeutic strategy? Alzheimers Dementia (2006) 2(3):164-8. doi:10.1016/j.jalz.2006.03.001.
124. Canela A, Vera E, Klatt P, Blasco MA. High-throughput telomere length quantification by FISH and its application to human population studies. Proc Natl Acad Sci U S A (2007) 104(13):5300-5. doi:10.1073/pnas.0609367104.
125. Grodstein F, van Oijen M, Irizarry MC, Rosas HD, Hyman BT, Growdon JH, et al. Shorter telomeres may mark early risk of dementia: preliminary analysis of 62 participants from the nurses' health study. PLoS One (2008) 3(2):e1590. doi:10.1371/journal.pone.0001590.
126. Valdes AM, Deary IJ, Gardner J, Kimura M, Lu X, Spector TD, et al. Leukocyte telomere length is associated with cognitive performance in healthy women. Neurobiol Aging (2010) 31(6):986-92. doi:10.1016/j.neurobiolaging.2008.07.012.
127. Lin J, Epel E, Blackburn E. Telomeres and lifestyle factors: roles in cellular aging. Mutat Res (2012) 730(1-2):85-9. doi:10.1016/j.mrfmmm.2011.08.003.
128. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A (2004) 101(49):17312-5. doi:10.1073/pnas.0407162101.
129. Epel ES, Lin J, Wilhelm FH, Wolkowitz OM, Cawthon R, Adler NE, et al. Cell aging in relation to stress arousal and cardiovascular disease risk factors. Psychoneuroendocrinology (2006) 31(3):277-87. doi:10.1016/j.psyneuen.2005.08.011.
130. Damjanovic AK, Yang YH, Glaser R, Kiecolt-Glaser JK, Nguyen H, Laskowski B, et al. Accelerated telomere erosion is associated with a declining immune function of caregivers of Alzheimer's disease patients. J Immunol (2007) 179(6):4249-54.
131. Shammas MA. Telomeres, lifestyle, cancer, and aging. Curr Opin Clin Nutr Metab Care (2011) 14(1):28-34. doi:10.1097/MCO.0b013e32834121b1.
132. Barcelo A, Pierola J, Lopez-Escribano H, de la Pena M, Soriano JB, Alonso-Fernandez A, et al. Telomere shortening in sleep apnea syndrome. Respir Med (2010) 104(8):1225-9. doi:10.1016/j.rmed.2010.03.025.
133. Prather AA, Puterman E, Lin J, O'Donovan A, Krauss J, Tomiyama AJ, et al. Shorter leukocyte telomere length in midlife women with poor sleep quality. J Aging Res (2011) 2011:721390. doi:10.4061/2011/721390.
134. Elvsashagen T, Vera E, Boen E, Bratlie J, Andreassen OA, Josefsen D, et al. The load of short telomeres is increased and associated with lifetime number of depressive episodes in bipolar II disorder. J Affect Disord (2011) 135(1-3):43-50. doi:10.1016/j.jad.2011.08.006.
135. Simon NM, Smoller JW, McNamara KL, Maser RS, Zalta AK, Pollack MH, et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry (2006) 60(5):432-5. doi:10.1016/j.biopsych.2006.02.004.
136. Martin-Ruiz C, Dickinson HO, Keys B, Rowan E, Kenny RA, Von Zglinicki T. Telomere length predicts poststroke mortality, dementia, and cognitive decline. Ann Neurol (2006) 60(2):174-80. doi:10.1002/ana.20869.
137. Yaffe K, Lindquist K, Kluse M, Cawthon R, Harris T, Hsueh WC, et al. Telomere length and cognitive function in community-dwelling elders: findings from the health ABC study. Neurobiol Aging (2011) 32(11):2055-60. doi:10.1016/j.neurobiolaging.2009.12.006.
138. Ravnik-Glavac M, Hrasovec S, Bon J, Dreo J, Glavac D. Genome-wide expression changes in a higher state of consciousness. Conscious Cogn (2012) 21(3):1322-44. doi:10.1016/j.concog.2012.06.003.
139. Dusek JA, Otu HH, Wohlhueter AL, Bhasin M, Zerbini LF, Joseph MG, et al. Genomic counter-stress changes induced by the relaxation response. PLoS One (2008) 3(7):e2576. doi:10.1371/journal.pone.0002576.
140. Sharma H, Datta P, Singh A, Sen S, Bhardwaj NK, Kochupillai V, et al. Gene expression profiling in practitioners of Sudarshan Kriya. J Psychosom Res (2008) 64(2):213-8. doi:10.1016/j.jpsychores.2007.07.003.
141. Creswell JD, Irwin MR, Burklund LJ, Lieberman MD, Arevalo JM, Ma J, et al. Mindfulness-based stress reduction training reduces loneliness and pro-inflammatory gene expression in older adults: a small randomized controlled trial. Brain Behav Immun (2012) 26(7):1095-101. doi:10.1016/j.bbi.2012.07.006.
142. Black DS, Cole SW, Irwin MR, Breen E, St Cyr NM, Nazarian N, et al. Yogic meditation reverses NF-kappaB and IRF-related transcriptome dynamics in leukocytes of family dementia caregivers in a randomized controlled trial. Psychoneuroendocrinology (2013) 38(3):348-55. doi:10.1016/j.psyneuen.2012.06.011.
143. Saatcioglu F. Regulation of gene expression by yoga, meditation and related practices: a review of recent studies. Asian J Psychiatr (2013) 6(1):74-7. doi:10.1016/j.ajp.2012.10.002.
144. Takimoto-Ohnishia E, Ohnishia J, Murakamia K. Mind-body medicine: effect of the mind on gene expression. Personal Med Univ (2012) 1(1):2-6. doi:10.1016/j.pmu.2012.05.001.
145. Cotman CW. The role of neurotrophins in brain aging: a perspective in honor of Regino Perez-Polo. Neurochem Res (2005) 30(6-7):877-81. doi:10.1007/s11064-005-6960-y.
146. Kalman J, Kitajka K, Pakaski M, Zvara A, Juhasz A, Vincze G, et al. Gene expression profile analysis of lymphocytes from Alzheimer's patients. Psychiatr Genet (2005) 15(1):1-6. doi:10.1097/00041444-200503000-00001.
147. Twine NA, Janitz K, Wilkins MR, Janitz M. Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease. PLoS One (2011) 6(1):e16266. doi:10.1371/journal.pone.0016266.
148. Katsel P, Li C, Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res (2007) 32(4-5):845-56. doi:10.1007/s11064-007-9297-x.
149. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis (2005) 8(3):247-68.
150. Pasinetti GM, Ho L. From cDNA microarrays to high-throughput proteomics. Implications in the search for preventive initiatives to slow the clinical progression of Alzheimer's disease dementia. Restor Neurol Neurosci (2001) 18(2-3):137-42.
151. Zanni GR, Wick JY. Telomeres: unlocking the mystery of cell division and aging. Consult Pharm (2011) 26(2):78-90. doi:10.4140/TCP.n.2011.78.
152. Kananen L, Surakka I, Pirkola S, Suvisaari J, Lonnqvist J, Peltonen L, et al. Childhood adversities are associated with shorter telomere length at adult age both in individuals with an anxiety disorder and controls. PLoS One (2010) 5(5):e10826. doi:10.1371/journal.pone.0010826.
153. Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E, Masterman D, et al. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol Aging (2003) 24(1):77-84. doi:10.1016/S0197-4580(02)00043-X.
154. Thomas P, Callaghan NJO, Fenech M. Telomere length in white blood cells, buccal cells and brain tissue and its variation with ageing and Alzheimer's disease. Mech Ageing Dev (2008) 129(4):183-90. doi:10.1016/j.mad.2007.12.004.
155. Lukens JN, Van Deerlin V, Clark CM, Xie SX, Johnson FB. Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease. Alzheimers Dement (2009) 5(6):463-9. doi:10.1016/j.jalz.2009.05.666.
156. Bekaert S, De Meyer T, Rietzschel ER, De Buyzere ML, De Bacquer D, Langlois M, et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell (2007) 6(5):639-47. doi:10.1111/j.1474-9726.2007.00321.x.
157. Armanios M, Alder JK, Parry EM, Karim B, Strong MA, Greider CW. Short telomeres are sufficient to cause the degenerative defects associated with aging. Am J Hum Genet (2009) 85(6):823-32. doi:10.1016/j.ajhg.2009.10.028.
158. Ornish D, Lin J, Daubenmier J, Weidner G, Epel E, Kemp C, et al. Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol (2008) 9(11):1048-57. doi:10.1016/S1470-2045(08)70234-1.
159. Kaszubowska L. Telomere shortening and ageing of the immune system. J Physiol Pharmacol (2008) 59:169-86.
160. Carrero J, Stenvinkel P, Fellstrom B, Qureshi AR, Lamb K, Heimburger O, et al. Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. J Intern Med (2008) 263(3):302-12. doi:10.1111/j.1365-2796.2007.01890.x.
161. Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry (2009) 22(1):32-6. doi:10.1097/YCO.0b013e328315a561.
162. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med (2009) 71(2):171-86. doi:10.1097/PSY.0b013e3181907c1b.
163. Motivala SJ, Sarfatti A, Olmos L, Irwin MR. Inflammatory markers and sleep disturbance in major depression. Psychosom Med (2005) 67(2):187-94. doi:10.1097/01.psy.0000149259.72488.09.
164. von Kanel R, Dimsdale JE, Ancoli-Israel S, Mills PJ, Patterson TL, McKibbin CL, et al. Poor sleep is associated with higher plasma proinflammatory cytokine interleukin-6 and procoagulant marker fibrin D-dimer in older caregivers of people with Alzheimer's disease. J Am Geriatr Soc (2006) 54(3):431-7. doi:10.1111/j.1532-5415.2005.00642.x.
165. Gouin JP. Chronic stress, immune dysregulation, and health. Am J Lifestyle Med (2011) 5(6):476-85. doi:10.1177/1559827610395467.
166. Pace TW, Negi LT, Adame DD, Cole SP, Sivilli TI, Brown TD, et al. Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinology (2009) 34(1):87-98. doi:10.1016/j.psyneuen.2008.08.011.
167. Pullen PR, Nagamia SH, Mehta PK, Thompson WR, Benardot D, Hammoud R, et al. Effects of yoga on inflammation and exercise capacity in patients with chronic heart failure. J Card Fail (2008) 14(5):407-13. doi:10.1016/j.cardfail.2007.12.007.
168. Cacabelos R. Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics (2004) 5(8):1049-105. doi:10.1517/14622416.5.8.1049.
169. Grunblatt E, Bartl J, Zehetmayer S, Ringel TM, Bauer P, Riederer P, et al. Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. J Alzheimers Dis (2009) 16(3):627-34. doi:10.3233/JAD-2009-0996.
170. Cedazo-Minguez A, Winblad B. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Exp Gerontol (2010) 45(1):5-14. doi:10.1016/j.exger.2009.09.008.
171. Maes OC, Xu S, Yu B, Chertkow HM, Wang E, Schipper HM. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging (2007) 28(12):1795-809. doi:10.1016/j.neurobiolaging.2006.08.004.